Literature DB >> 10788752

Reversible frontal lobe syndrome associated with influenza virus infection in children.

S Sato1, S Kumada, T Koji, M Okaniwa.   

Abstract

Two patients, a 3-year-old female and a 1-year-old female, both with a focal encephalopathic process associated with influenza A virus infection, are reported. Both children had neuropsychologic signs suggesting frontal and limbic dysfunction, without disturbances of consciousness or motor function, and had good recoveries. The results of single-photon emission computed tomography and electroencephalography support the finding of reversible impairment of the frontal and limbic areas. Focal reversible encephalopathy has rarely been reported in association with influenza virus infection, although it often provokes diffuse encephalopathies, with a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10788752     DOI: 10.1016/s0887-8994(99)00150-2

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  4 in total

1.  Acute Infantile Encephalopathy Predominantly Affecting The Frontal Lobes (AIEF).

Authors:  Sarbani Raha; Vrajesh Udani
Journal:  Indian J Pediatr       Date:  2011-12-20       Impact factor: 1.967

Review 2.  Influenza-associated neurological complications.

Authors:  Jenny P Tsai; Andrew J Baker
Journal:  Neurocrit Care       Date:  2013-02       Impact factor: 3.210

3.  Oseltamivir reduces hippocampal abnormal EEG activities after a virus infection (influenza) in isoflurane-anesthetized rats.

Authors:  Youssouf Cissé; Isao Inoue; Hiroshi Kido
Journal:  J Exp Pharmacol       Date:  2012-06-21

4.  Encephalopathy in pediatric patients after allogeneic hematopoietic stem cell transplantation is associated with a poor prognosis.

Authors:  P Woodard; K Helton; H McDaniel; R B Khan; S Thompson; G Hale; E Benaim; K Kasow; W Leung; E Horwitz; D K Srivastava; X Tong; U Yusuf; J M Cunningham; R Handgretinger
Journal:  Bone Marrow Transplant       Date:  2004-06       Impact factor: 5.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.